| Administered 250 μg within 28 gestational weeks |
antenatal 1/A |
| Administered 300 μg within 28 gestational weeks |
antenatal 2/B |
| Administered 50 μg within 28 and 34 gestational weeks |
antenatal 3/C |
| Administered 100 μg between 28 and 34 gestational weeks |
antenatal 4/D |
| Administered 300 μg between 28 and 34 gestational weeks |
antenatal 5/E |
| Placebo or blank control group |
blank/F |
| Administered 100 μg ≤ dosage < 200 μg within 72 h postpartum |
postnatal 1/G |
| Administered 200 μg ≤ dosage < 300 μg within 72 h postpartum |
postnatal 2/H |
| Administered 300 μg ≤ dosage < 500 μg within 72 h postpartum |
postnatal 3/I |
